pembrolizumab,enfortumab vedotin
merck,astellas,seagen
['ev 103', 'bladder', ' ev ']
 ev 103 cohort k
cis unfit #bladdercancer 1l oor 61.4 % 65.4 % of responders were still respondig at 12 months
#esmo22 
Uro Oncology
Engine of growth
Buenos Aires 
Argentina